Further evaluation of a heparin neutralizer and its effect on factor IX in normal and coumadin-plasma.
Heparsorb, a commercial anion exchange resin capable of removing large amounts of heparin from heparinized plasma, has recently been introduced into the clinical diagnostic laboratory as a useful reagent for the evaluation of blood coagulation in heparinized blood and the evaluation of an unexpected prolongation of global coagulation tests. In this paper data are presented which indicate that Heparsorb has little or no effect on the activities of blood coagulation factors in heparinized plasma, except for a modest (22%) reduction in factor IX-activity. Maximal loss of factor IX-activity was observed after incubation of plasma with Heparsorb for 15 min at room temperature. Prolonged storage of plasma before or after incubation with Heparsorb and changes in plasma pH had no appreciable effect on the extent of factor IX-activity loss. Evidence is presented to substantiate earlier findings that factor IX-activity is not removed by Heparsorb from plasma of patients on coumadin therapy, and to indicate that this lack of effect of Heparsorb on factor IX-activity in coumadin plasma is due to reduced affinity of hypocarboxy-IX for the heparin neutralizing resin.
D001780:Blood Coagulation Tests; D002482:Cellulose / Q000031:analogs & derivatives*; D003636:DEAE-Cellulose / Q000031:analogs & derivatives* / Q000494:pharmacology; D005164:Factor IX / Q000378:metabolism*; D006493:Heparin / Q000097:blood*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D013696:Temperature; D013997:Time Factors; D014859:Warfarin / Q000097:blood*
D014859:Warfarin; D005164:Factor IX; D002482:Cellulose; D006493:Heparin; D003636:DEAE-Cellulose; C010359:triethylaminoethyl cellulose